January 31, 2020 – Zenzium, Ltd., announced today its participation in a groundbreaking trial in Greater Manchester which is to test cutting edge wearable technology in combination with Artificial Intelligence (AI) for patients who have received cancer treatment. Called, EMBRaCE, (Enhanced Monitoring for Better Recovery and Cancer Experience), the trial is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust, The University of Manchester, Aptus Clinical and Zenzium, Ltd. The trial has opened initially for blood cancer, lung, and colorectal cancer patients and will run across Greater Manchester. Using commercially available health sensors and devices in combination with AI could reveal digital fingerprints associated with vital signs and other clinical data that could allow doctors to assess the progress of their patients and potentially improve patient outcomes. The technologies under investigation include: • a smart ring, worn on any finger made by Oura Health • the Withings ScanWatch, a hybrid smartwatch • the Isansys system, which is worn on the chest • AI capabilities developed and provided by Zenzium The technologies can assess a range of vital signs, including electrocardiogram (ECG), heart rate, temperature, physical activity levels and sleep.

Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK's innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease. Artificial Intelligence will automatically analyse and learn from data generated by the patient at home, using easy-to-use medical monitors and wearables, which connect to Aseptika's Activ8rlives App. The companies will introduce a Smart LungHealth system in the form of the Cloud-connecting Activ8rlives4 App and will also embed the AI alerting system into Aseptika's future wearable medical monitor called the BuddyWOTCH, currently in development. Aseptika and Zenzium will collaborate to create a system to automatically warn when patients health is declining. Looking at anonymised information gathered from previous clinical trials showed that many patients do not treat exacerbations and may not even be aware that they are having them.